CJC-1295 + IpamorelinResearch-Grade GH Secretagogue CombinationTagline: Synergistic GH Release Research

Product Description

CJC-1295 + Ipamorelin is a research peptide combination pairing CJC-1295, a Growth Hormone Releasing Hormone (GHRH) analogue, with Ipamorelin, a selective ghrelin receptor agonist. Researchers study this combination for its synergistic effects on pulsatile growth hormone (GH) release and IGF-1 signaling pathways.

This research formulation is commonly utilized in laboratory investigations involving:

• growth hormone secretion dynamics

• IGF-1 production

• metabolic regulation

• recovery physiology

• body composition research

• endocrine signaling pathways

• regenerative and longevity-related models

Researchers value this combination for its ability to stimulate both hypothalamic and pituitary mechanisms associated with GH regulation.

Why Researchers Choose CJC-1295 + Ipamorelin

• Dual-pathway stimulation targeting both GHRH and ghrelin receptor pathways

• Frequently studied for pulsatile GH release patterns

• Relevant in IGF-1 and metabolic signaling research

• Ipamorelin’s selective receptor profile minimizes off-target activity in research models

• High-purity formulation suitable for controlled laboratory use

• Consistent batch quality for reproducible experimental results

Product Specifications

• Research Grade

• High-Purity Formulation

• Laboratory Tested

• Research Use Only

Important Notice

For laboratory and scientific research purposes only. Not for human consumption, veterinary use, medical treatment, or diagnostic applications. Must be 21 years or older to purchase.